Document Detail


The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2).
MedLine Citation:
PMID:  23154590     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Observational studies have shown that 24-h and morning ambulatory blood pressure (BP) control is low. This large-scale, practice-based study evaluated the effects of telmisartan 40 or 80 mg alone or in combination with hydrochlorothiazide (HCTZ) 12.5 mg on these BP parameters over 8 weeks; treatment was adjusted if clinic BP remained ≥140/90 mm Hg. A total of 863 patients were evaluated (baseline mean clinic BP, morning and 24-h ambulatory BP: 155±15/93±10 mm Hg, 137±15/83±11 mm Hg, 133±14/79±10 mm Hg, respectively; 68% were previously treated at baseline). Telmisartan with/without HCTZ significantly reduced the mean morning ambulatory BP (-8.2/-4.9 mm Hg), daytime ambulatory BP (-8.0/-4.7 mm Hg), 24-h ambulatory BP (-7.9/-4.7 mm Hg) and clinic BP (-22.3/-13.2 mm Hg) (all P<0.001) in previously untreated and in treated patients who switched to telmisartan and telmisartan/HCTZ. After treatment with telmisartan with/without HCTZ, the morning ambulatory BP control increased from 36.5 to 64.4%; daytime ambulatory BP control increased from 40.8 to 67.6%; 53.0% of patients achieved 24-h ambulatory BP <125/80 mm Hg and 62% achieved <130/80 mm Hg targets. Only 0.8% (7/863) reported an adverse event. In summary, telmisartan and telmisartan/HCTZ increased smooth 24-h BP control in daily management of hypertension.
Authors:
Gianfranco Parati; Grzegorz Bilo; Josep Redon;
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2012-11-15
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  36     ISSN:  1348-4214     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-05     Completed Date:  2013-09-25     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  322-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Aged
Aged, 80 and over
Ambulatory Care
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Benzimidazoles / adverse effects,  therapeutic use*
Benzoates / adverse effects,  therapeutic use*
Blood Pressure / drug effects*
Blood Pressure Monitoring, Ambulatory
Circadian Rhythm
Drug Combinations
Drug Therapy, Combination
Female
Humans
Hydrochlorothiazide / adverse effects,  therapeutic use*
Hypertension / drug therapy*
Male
Middle Aged
Reference Values
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; 0/Drug Combinations; 0/telmisartan, hydrochlorothiazide drug combination; 0J48LPH2TH/Hydrochlorothiazide; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis.
Next Document:  Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advance...